Actively Recruiting
Czech AATD Registry
Led by Thomayer University Hospital · Updated on 2022-01-05
300
Participants Needed
1
Research Sites
939 weeks
Total Duration
On this page
Sponsors
T
Thomayer University Hospital
Lead Sponsor
M
Masaryk University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Alpha-1-antitrypsin deficiency is the most common congenital disease of the respiratory system, leading to early pulmonary emphysema or bronchiectasis. Pulmonary involvement significantly accelerates active cigarette smoking. Patients with alpha-1-antitrypsin deficiency may also have liver cirrhosis, vasculitis, skin or intestinal disorders. The AATD Registry is a non-interventional multicenter retrospective prospective longitudinal follow-up of patients with alpha-1-antitrypsin deficiency. The aim of the AATD National Registry is to collect and analyze clinical data in patients with alpha-1 antitrypsin deficiency.
CONDITIONS
Official Title
Czech AATD Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with alpha-1-antitrypsin deficiency
You will not qualify if you...
- Patient disagreement with inclusion in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Thomayer university hospital
Prague, Czech Republic, Czechia, 14059
Actively Recruiting
Research Team
K
Katerina Kusalova, Ing
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here